Contributions of SchematicScout

Contributions by SchematicScout, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 6,022 edits includes activity predating the current log.

1. 05:25, 16 Apr 2026 (diff | hist) Counterfeit peptide 5,488 ±0 add the note that a purity figure without water and counterion is not a mass
2. 23:02, 26 Dec 2025 (diff | hist) CagriSema 5,687 ±0 expand §Rationale
3. 23:06, 31 Oct 2025 (diff | hist) HOMA-IR 4,511 ±0 expand §Behaviour under weight loss and incretin therapy
4. 01:10, 24 Aug 2025 (diff | hist) Global access disparity 4,275 ±0 m expand §Consequences and framing
5. 19:51, 31 Jul 2025 (diff | hist) LEADER trial 4,171 ±0 m de-orphan
6. 23:28, 27 Apr 2025 (diff | hist) Peptide aggregation 4,377 ±0 state the column chemistry and the gradient the figure was obtained on
7. 07:41, 17 Apr 2025 (diff | hist) USP General Chapter 71 3,363 ±0 m add the repeatability figure with the number of injections
8. 18:18, 16 Mar 2025 (diff | hist) Melanotan II 3,391 +33 the sequence in the infobox was missing the C-terminal amide; added
9. 16:49, 8 Mar 2025 (diff | hist) WuXi TIDES 10,186 +498 m add the reception tally with its period and count stated
10. 17:11, 26 Feb 2025 (diff | hist) Incretin effect 5,425 ±0 clarify that concentrations differ substantially between assay platforms
11. 17:26, 5 Jan 2025 (diff | hist) Triple agonist 3,120 +574 the lead claimed weekly dosing for a compound dosed daily; corrected
12. 03:10, 18 Oct 2024 (diff | hist) Cagrilintide 2,406 ±0 add the peptide length to the infobox
13. 01:02, 25 Sep 2024 (diff | hist) Proglucagon 3,075 +146 clarify that concentrations differ substantially between assay platforms
14. 01:55, 22 Jun 2024 (diff | hist) Peptide 1,981 ±0 add the figure for the lyophilisation cycle and caption it